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Sumit Gupta1,5*, Jason D Pole2,3, Astrid Guttmann3,4,5 and Lillian Sung1,5Abstract
Background: Administrative databases and cancer registries are frequently used to conduct population-based
research, but often lack clinical data necessary for risk stratification. Our objective was to determine the criterion
validity of a risk-stratification algorithm based on treatment characteristics available from a pediatric cancer registry
as a proxy for disease risk, by comparing it to traditional biology-based risk classifications.
Methods: We identified all children with acute lymphoblastic leukemia diagnosed at a single institution between
January 2000 and June 2011, and linked them to a population-based cancer registry. Several risk algorithms were
then constructed using disease risk variables collected through chart review by a pediatric oncologist, and
compared to a risk algorithm based on treatment protocol name and age, available from the registry.
Results: Of 596 patients identified, 579 (97.1%) met inclusion criteria and were successfully linked. The registry-based
algorithm showed almost perfect agreement with a biology-based algorithm based on age, initial white blood cell
count, immunophenotype and cytogenetics (kappa=0.85, 95th confidence interval 0.81-0.90). Discrepant cases were
often due to the presence of unusual high risk features not captured by standard disease-risk variables but reflected in
clinicians’ choices of higher intensity treatment protocols.
Conclusions: Protocol name represents a valid proxy of disease risk, allowing for risk stratification while conducting
comparative effectiveness research using cancer registries and health services data. Future studies should examine the
validity of treatment-based risk algorithms in other malignancies and using other treatment characteristics commonly
found in health services data, such as the receipt of specific chemotherapeutic agents.
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The past several decades have witnessed remarkable
advances in the treatment of childhood cancer, with
overall cure rates now exceeding 80% [1-3]. However, in
many cases significant differences exist between outcomes
reported from clinical trials and population-based data.
For example, Hunger et al. recently reported that children
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reproduction in any medium, provided the or(ALL) treated on Children’s Oncology Group clinical trials
between 2000–2005 had a 5-year survival rate of 76% [4].
By contrast, registry data for 15–19 year olds diagnosed
with ALL over a similar time period showed a far lower
5-year survival of 50.1% [3]. In addition to allowing better
capture of population survival trends, cancer registries
and health services databases have also been used in
pediatric oncology to conduct comparative effectiveness
research, identify survivors at high risk of long term me-
dical and socioeconomic adverse effects, and monitor the
uptake of new therapeutic interventions [5-9].
While routinely collected population-based data holds
significant potential, it can also introduce new biases. One
major limitation in many of these datasets is the inability
to risk stratify patients. In childhood cancer, detailedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mation is used to determine the risk of mortality and
other adverse outcomes; prognosis and treatment can vary
widely within a single malignancy based on this informa-
tion [10,11]. These detailed biologic data are rarely col-
lected by cancer registries or administrative databases, as
highlighted by a recent review of data sources for cancer
comparative effectiveness research [12]. Thus important
potential confounding information is often unavailable,
limiting confidence in the conclusions of studies using
these resources.
A valid method of risk stratification using information
available in population-based databases would increase
the contribution of these data. Treatment-based risk as-
signment may offer such a method. In pediatric cancer,
treatment intensity is often based on disease risk and
biologic prognostic factors; high-risk subtypes of a par-
ticular malignancy will receive higher intensity treatment
[10,11,13]. Treatment information is often collected in
population-based databases: cancer registries may collect
the names of treatment protocols while health services
databases may collect information on the administration
of particular chemotherapeutic agents [8,14].
Our objective was therefore to determine the criterion
validity of a registry-based risk-stratification algorithm
using treatment protocol name and age by comparing it
to several traditional biology-based risk classifications.




The study population included all children diagnosed
with primary ALL between June 1, 2000 and December
31, 2011 at The Hospital for Sick Children, Toronto,
Canada. The Hospital for Sick Children is a pediatric
tertiary care institution that sees over 300 new cases
of childhood cancer per year. Non-Ontario residents,
children for whom no active treatment was pursued,
and children transferred to other centers within the first
month of treatment were excluded. Patients were identi-
fied using a local institutional electronic database. ALL
was chosen as it has one of the most refined risk deter-
mination classifications in pediatric oncology, incorpor-
ating multiple biologic factors [10].
Data sources and variables
Factors collected for each patient by chart review were:
age at diagnosis, initial white blood cells (WBC) at diag-
nosis, immunophenotype/lineage, leukemia cytogene-
tics, and the presence of minimally residual disease
(MRD) at the end of induction therapy. Cytogenetic
abnormalities considered high risk included t(9;22)
(BCR-ABL), hypodiploidy (<45 chromosomes), and any11q23 (MLL) rearrangement [15,16]. MRD was assessed
by flow cytometry; ≥0.01% residual blasts in bone marrow
at the end of induction was considered positive [17].
These variables were chosen a priori based on both their
accepted use in contemporary ALL risk stratification and
the ease of their availability in patient charts [10].
POGONIS is a population-based registry that prospec-
tively captures all cases of pediatric cancer diagnosed and
treated at one of the five tertiary pediatric oncology cen-
ters in Ontario. POGONIS personnel assign each patient
a unique numeric identifier, which is retained both by the
treating centers and POGONIS. This number was there-
fore used to link study patients to POGONIS. Approxi-
mately 98% of Ontario children with cancer aged 0–14, as
identified by the Ontario Cancer Registry (OCR), are
captured in POGONIS [14]. Basic demographic, treatment
and outcome variables are available in POGONIS. Though
various biologic fields have been introduced into POGONIS
at different times, they are variably collected between cen-
ters and often incompletely available. Therefore only treat-
ment protocol and age at diagnosis were utilized from
POGONIS for this study.
Multiple protocols for an individual child could be listed
in POGONIS if clinicians changed treatment based on
toxicity, non-response, or new prognostic information.
Any subsequent protocol recorded within four weeks of
the start of the first protocol was therefore identified and
compared to the first. In such cases, the more specific
protocol was ultimately assigned to the patient. For ex-
ample, the specific protocol “AALL0331” was chosen over
the more generic “three drug induction”. Where two spe-
cific protocols were identified, the one with a later start
date was chosen in order to better reflect risk prognostica-
tors available after diagnosis.
A pediatric oncologist identified patients, determined
eligibility and conducted the chart abstraction for all pa-
tients. At the time of chart review, the abstractor was
blinded to all patient registry data.
Creation of risk algorithms
Biology-based risk algorithms were created using vari-
ables abstracted by chart review while a registry-based
risk algorithm was created using treatment protocol
name listed in POGONIS and age at diagnosis. Multiple
biology-based risk algorithms were constructed using
these data to divide patients into standard and high risk
strata. Within each of these algorithms, the presence of
any high risk feature resulted in classification in the high
risk stratum. The first algorithm utilized only age and pre-
senting WBC according to the National Cancer Institu-
tion/Rome criteria (standard risk = age ≥1 year and <10
years, and WBC <50×109/L) [18]. Subsequent algorithms
added additional prognosticators in order to produce se-
quentially more sophisticated risk classifications using the
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poor risk cytogenetics, and presence of MRD (Table 1).
Where a prognosticator was not available for a particular
patient, the algorithm treated it as non-informative.
All treatment protocols used during the study period
were a priori classified as standard or high risk based on
protocol inclusion and exclusion criteria (Table 2). Protocol
inclusion criteria tend to mirror contemporaneous know-
ledge of favorable and unfavorable risk factors. Thus the in-
clusion criteria of past protocols do not perfectly align with
modern definitions of standard or high risk. All protocols
were therefore classified according to whether treating
physicians at the time would have considered them stand-
ard or high risk. All protocol risk assignments were made
through the consensus of two pediatric oncologists.
Age and protocol risk classification were then used to
create a registry-based risk algorithm. Patients aged 1–9
years at diagnosis and treated on a protocol classified
as standard risk were designated as standard risk.
Patients <1 year at diagnosis, ≥10 years at diagnosis or
treated on a protocol classified as high risk were desig-
nated as high risk.
All biology-based and registry-based risk algorithms
were created prior to the collection of any patient data.
Analysis
The agreement between the registry-based risk algorithm
and each of the biology-based risk algorithms was assessed
using the kappa statistic (0.00-0.20 slight; 0.21-0.40 fair;
0.41-0.60 moderate; 0.61-0.80 substantial; 0.81-1.00 almost
perfect) [19]. The charts of discrepant cases were reviewed
in detail in order to identify possible reasons for discord-
ance. Statistical analyses were performed using SAS-PC
software (version 9.2; SAS Institute, Cary, NC). Ethics ap-
proval was obtained from The Hospital for Sick Children.
Results
A total of 596 patients were diagnosed during the study
period. Twelve children were excluded: seven were not
Ontario residents, three were transferred to other cen-
ters within a week of starting treatment, one represented
a second malignancy, and one had no treatment pursuedTable 1 Biology-based risk algorithms using data available fr
Age (years) WBC (x109/L) Immuno
1 - 9 <1, ≥10 <50 ≥50 B
Algorithm 1* SR HR SR HR -
Algorithm 2* SR HR SR HR SR
Algorithm 3* SR HR SR HR SR
Algorithm 4* SR HR SR HR SR
HR High risk, MRD Minimally residual disease, SR Standard risk, WBC White blood ce
*For each algorithm, patients were classified as standard risk only in the absence of
&High risk cytogenetics included t(9;22) (BCR-ABL), hypodiploidy (<45 chromosome
#MRD positivity was defined as ≥0.01 residual blasts.due to underlying comorbidities. Of the remaining 584,
579 (99.1%) were successfully linked to POGONIS. All
five unlinked patients were diagnosed in the last 21 days
of 2011 and had therefore not yet been registered in
POGONIS at the time of data analysis.
The median age of the cohort was 4 years (interquar-
tile range 3–8). A total of 343 (59%) patients were male.
Disease-related characteristics of the cohort can be seen
in Table 3. MRD results were only available on approxi-
mately half of the cohort as this investigation was only
introduced into routine practice in 2005. The vast ma-
jority of patients were treated with defined protocols;
treatment protocols were assigned for all but four of the
study patients (575/579; 99.3%). Two patients died prior
to or shortly after starting treatment, while no reason
could be identified for the lack of listed protocol in the
remaining two. The most commonly used protocols
were from the Children’s Oncology Group: AALL0331
and AALL0232, accounting for 184 (31.8%) and 107
(18.48%) of patients respectively.
The number of children classified as standard risk by
the biology-based algorithms varied from 62.0% (algo-
rithm 1 [simplest] - age and WBC) to 56.0% (algorithm 4
[most complex] – incorporating all factors of age, WBC,
immunophenotype, cytogenetics and MRD) (Table 3). The
registry-based algorithm classified 56.7% of patients as
standard risk. Table 3 also illustrates the distribution of
each disease characteristic by risk category, and its va-
riation across algorithms.
Table 4 shows the agreement between the registry-
based classification and the biology-based algorithms.
Agreement was excellent (k ≥ 0.80) in all cases [19,20].
The best agreement as judged by the kappa statistic was
between the registry-based algorithm and algorithms 2
(age, WBC, and immunophenotype) and 3 (age, WBC,
immunophenotype and cytogenetics).
A total of 14 patients were classified as standard risk
by the registry-based algorithm but as high risk by the
biology-based algorithm 3. In two cases, this was due to
data entry errors within POGONIS. In the remaining 12
cases, the misclassification was due to disease features
currently known to be adverse prognosticators butom chart review
phenotype Cytogenetics& MRD#
T Low risk High risk Negative Positive
- - - - -
HR - - - -
HR SR HR - -
HR SR HR SR HR
ll.
any high risk feature.
s), or any 11q23 (MLL) rearrangement.
Table 2 Registry-based algorithm based on treatment protocol name and details of each treatment protocol
Protocol Lineage Age (years) WBC (x109/L) Genetics Other Risk assignment
AALL02P2 T ≥10 (or)* ≥50 (or) HR
AALL0031 t(9;22) or hypodiploidy or MLL
with slow response (or)
Induction failure (or) HR
AALL0232 B ≥10 (or) ≥50 (or) Steroid pre treatment (or) HR
AALL0331 B 1-9 <50 SR
AALL0434 T >1 HR
AALL0622 >1 t(9;22) HR
AALL0631 <1 HR
AALL0932 B 1-9 <50 No t(9;22), MLL, iAMP21,
hypodiploidy
SR
CCG1991 B 1-9 <50 SR
POG9201 B 1-9 <50 Trisomy 4,10, DI>1.16 or t(12;21);
No t(9;22), 1;19, MLL
SR
POG9407 <1 HR
POG9605 B 1-9 <50 No trisomy 4,10, DI>1.16, MLL,
t(1;19), t(9;22)
SR
B ≥10 <50 Trisomy 4,10 or DI>1.16; No MLL,
t(1;19), t(9;22)
SR
B >1 ≥50 Trisomy 4,10 or DI>1.16; No MLL,
t(1;19), t(9;22)
SR
POG9904 B 1-9 <50 Trisomy 4,10, DI>1.16 or t(12;21);
No MLL, t(1;19), t(9;22)
SR
POG9905 Neither 9904, 9906 nor AALL0031 SR
POG9906 B M>12; F>16 (or) >100 (or) MLL (or) HR
B Sliding scale of WBC criteria for M age 8–11 and F age 12-15 HR
Protocol C <1 or >10 (or) >20 (or) t(9;22) or MLL (or) L2 morphology, mediastinal mass,
or massive LN/HSM
HR
DI DNA index, F Female, HR High risk, HSM Hepatosplenomegaly, iAMP Intra-amplification, LN – Lymphadenopathy, M Male, SR Standard risk, WBC White blood cell.
*(or) indicates factors for which any one was sufficient for inclusion into the protocol.
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presentation (e.g. specific high-risk cytogenetic abnor-
malities). A further 27 patients were classified as high risk
by the registry-based algorithm and as standard risk by
the biology-based algorithm 3. Seven cases were due to
data entry errors, predominantly in protocol name. Twelve
cases were due to the presence of risk factors other than
the a priori specified biology-based factors obtained by
chart review, such as central nervous system involvement,
testicular involvement, and steroid pre-treatment. In the
remaining cases, clinicians chose high-risk treatment pro-
tocols for individualized reasons despite patients meeting
standard risk criteria. A common example among these
remaining cases involved the WBC count at diagnosis:
several children presented with counts of <50×109/L (thus
meeting standard risk criteria), but which then shortly rose
to ≥50×109/L prior to the start of therapy.
Discussion
We found that for children with ALL, a risk stratifica-
tion system based on treatment protocol as recorded ina population-based pediatric cancer registry was a valid
proxy of disease risk as compared to biology-based risk
algorithms. Agreement between the registry-based al-
gorithm and the biology-based algorithm incorporating
age, WBC, immunophenotype and cytogenetics was
almost perfect, with a kappa of 0.85 (95% confidence
interval 0.81 to 0.90).
Though still almost perfect, agreement between the
registry-based algorithm was lower with algorithm 1 (age,
WBC; k = 0.80) and with algorithm 4 (all biologic prog-
nosticators, including MRD; k =0.83). The registry-based
classification was likely superior to the simplest algorithm
incorporating only age and initial WBC (algorithm 1), as a
portion of children considered standard risk by age and
WBC will in fact have high risk immunophenotypic or
cytogenetic features (Table 3); this was reflected in the
treatment given to them. By contrast, as MRD results are
only available approximately five weeks after starting treat-
ment, it is unlikely that our protocol-based algorithm as
currently defined captured MRD-based changes in treat-
ment. However, high risk cytogenetics and MRD positivity
Table 3 Disease-related characteristics of overall study cohort and distribution of each characteristic by biology-based
algorithms (N=579)
Algorithm 1* Algorithm 2* Algorithm 3* Algorithm 4*
Age, WBC Algorithm 1+ immunophenotype Algorithm 2+cytogenetics Algorithm 3+MRD
Overall SR HR SR HR SR HR SR HR
Overall 579 (100) 359 (62) 220 (38) 347 (60) 232 (40) 340 (59) 239 (41) 324 (56) 255 (44)
Immunophenotype
B 522 (90) 347 (66) 175 (34) 347 (66) 175 (34) 340 (65) 182 (35) 324 (62) 198 (10)
T 57 (10) 12 (21) 45 (79) 0 (0) 57 (100) 0 (0) 57 (100) 0 (0) 57 (100)
Cytogenetics
High risk 36 (6) 7 (19) 29 (81) 7 (19) 29 (81) 0 (0) 36 (100) 0 (0) 36 (100)
MLL rearrangement 19 (3) 3 (16) 16 (84) 3 (16) 16 (84) 0 (0) 19 (100) 0 (0) 19 (100)
t(9;22) (BCR-ABL) 10 (2) 2 (20) 8 (80) 2 (20) 8 (80) 0 (0) 10 (100) 0 (0) 10 (100)
Hypodiploidy 7 (1) 2 (29) 5 (71) 2 (29) 5 (71) 0 (0) 7 (100) 0 (0) 7 (100)
Standard risk 542 (94) 352 (65) 190 (35) 340 (63) 202 (37) 340 (63) 202 (37) 324 (60) 218 (40)
Hyperdiploidy 183 (32) 147 (80) 36 (20) 147 (80) 36 (20) 147 (80) 36 (20) 143 (78) 40 (22)
t(12;21) (TEL-AML) 144 (25) 116 (81) 28 (19) 116 (81) 28 (19) 116 (81) 28 (19) 115 (80) 29 (20)
t(1;19) (E2A-PBX) 22 (4) 12 (55) 10 (45) 12 (55) 10 (45) 12 (55) 10 (45) 10 (45) 12 (55)
No specific lesion 193 (33) 77 (40) 116 (60) 65 (34) 128 (66) 65 (34) 128 (66) 56 (29) 137 (71)
Missing 1 (0) 0 (0) 1 (100) 0 (0) 1 (100) 0 (0) 1 (100) 0 (0) 1 (100)
MRD
Negative 258 (45) 189 (73) 69 (27) 189 (73) 69 (27) 185 (72) 73 (28) 185 (72) 73 (28)
Positive 38 (5) 18 (47) 20 (53) 18 (47) 20 (53) 16 (42) 22 (58) 0 (0) 38 (100)
Died prior to test 6 (1) 1 (17) 5 (83) 1 (17) 5 (83) 1 (17) 5 (83) 1 (17) 5 (83)
Not performed 277 (48) 151 (55) 126 (45) 139 (50) 138 (50) 139 (50) 138 (50) 139 (50) 138 (50)
All values represent N (%).
IQ , Interquartile range; HR, High risk; MRD, Minimally residual disease; N, Number; SR, Standard risk; WBC, White blood cell.
Gupta et al. BMC Medical Research Methodology 2013, 13:68 Page 5 of 7
http://www.biomedcentral.com/1471-2288/13/68are often related [17,21]. Algorithms that take cytogenetics
into account either directly or indirectly (i.e. through
treatment protocol) will therefore reflect a portion of the
prognostic ability of MRD. It should also be noted that
differences between kappa statistics in this study were
small, and may in fact have been due to chance alone.
Though a minority of discrepant cases was due to data
entry errors, the majority could be classified into one of
three categories. The first group of discordant cases was
secondary to the discrepancy between current and past
knowledge of disease prognosticators. In ALL for ex-
ample, new cytogenetic abnormalities associated with
poor outcomes continue to be discovered [22,23]. NewTable 4 Measures of agreement between the registry-based a
Biology-based algorithms Sens
Algorithm 1 (Age, WBC) 0
Algorithm 2 (Age, WBC, immunophenotype) 0
Algorithm 3 (Age, WBC, immunophenotype, cytogenetics) 0
Algorithm 4 (Age, WBC, immunophenotype, cytogenetics, MRD) 0
*Note that sensitivity, specificity, PPV and NPV were calculated for the ability of the
the various biology-based algorithms.
CI, Confidence interval; MRD, Minimally residual disease; NPV, Negative predictive vadiscoveries take time to be incorporated into clinical
practice, such that past children with these risk features
may not have had their treatment modified. This
resulted in their misclassification as standard risk by the
registry-based algorithm.
In the second group, several children had high risk
factors that were not specified a priori by the standard-
ized chart review. For example, the inadvertent pre-
treatment with steroid of children with ALL is widely
considered to increase the risk for poor outcome [24].
Despite this, investigators rarely present risk stratifica-
tion by steroid pretreatment when reporting outcomes,
likely due to its relative rarity and inconsistent reportinglgorithm and the biology-based algorithms*
itivity Specificity PPV NPV Kappa, 95th CI
.95 0.88 0.83 0.97 0.80 (0.76-0.86)
.95 0.91 0.88 0.97 0.85 (0.81-0.89)
.94 0.96 0.89 0.96 0.85 (0.81-0.90)
.90 0.93 0.91 0.92 0.83 (0.78-0.87)
registry-based algorithm to correctly identify high risk patients as defined by
lue; PPV, Positive predictive value; WBC, White blood cell.
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tain, even through chart review. It is worth noting that in
the current validation study, treating clinicians were of
course aware of these factors and accordingly prescribed
higher intensity treatment protocols. Registry-based algo-
rithms incorporating treatment protocol therefore seem
to accurately reflect the presence of such prognosticators.
Finally, in the third group, patients met technical stand-
ard risk criteria but were nonetheless treated on high risk
protocols by their physicians. For example, NCI standard
risk criteria are based on the first WBC at the treating in-
stitution. In several cases however, when a presenting
WBC <50×109/L rapidly increased to ≥50×109/L prior to
treatment initiation, clinicians chose to base risk stratifica-
tion on the latter value. Again, treatment protocol func-
tioned as a proxy of physicians’ overall impression of
disease risk, both when physicians adhered to or deviated
from standardized risk criteria. These examples also illus-
trate how the utility of cancer registries for population-
based research is dependent on the alignment of data
capture strategies with clinical applicability [12].
Strengths of this study include the large sample size and
the ability to successfully link local data to population-
based registry records. A significant limitation is the ability
to generalize our findings to different malignancies and
treatment protocols. Some cooperative groups treat ALL
with protocols whose names do not differ by risk strata, or
where multiple treatment strata are contained within a
single protocol name. Osteosarcoma provides another
example; though the presence of metastases carries a far
worse survival than localized disease, the treatment is
generally the same [26]. Treatment-based risk algorithms
would therefore not be a valid proxy of disease risk. In
addition, some population-based registries may not collect
treatment protocol names. Other ways of defining treat-
ment intensity such as the use of specific chemothera-
peutic agents or length of treatment have been used but
require validation [27]. Even where other registries do
collect protocol name, local validation analyses similar to
that carried out in this study are likely to still be necessary
before further analyses requiring risk stratification can be
conducted.
A second limitation concerns the generalizability to
other jurisdictions. It is possible that treatment assign-
ment practices vary between institutions, with other
centers less likely to use standardized chemotherapy
protocols. However, pediatric oncology enjoys a greater
degree of standardization than most medical disciplines.
Almost all centers treating childhood cancer belong to
large cooperative trial groups, and previous research has
shown that a majority of cancer patients less that 15
years of age are registered in clinical trials across vir-
tually all metropolitan and rural areas across the United
States [28,29]. Finally, while the method presented inthis paper is a valid way of approximating disease risk,
and therefore in predicting survival and relapse-based
outcomes, its ability to predict other outcomes (e.g.
long-term side effects of treatment) is unknown.
Conclusions
In conclusion, in this study we found that a registry-
derived algorithm based on treatment protocol name and
age at diagnosis was a valid method of approximating
disease risk. Future studies may consider using treatment-
based algorithms for the purpose of risk stratification
when conducting registry-based research in pediatric on-
cology, though validation in other malignancies and using
other indicators of treatment intensity is required.
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